The Alliance for the Adoption of
Innovations in Medicine (Aimed Alliance) believes Americans are better
served through policies that define the value of new therapies in
patient terms, not upfront costs. This means assessing novel therapies
on the basis of improved longevity, productivity, and quality of life
where the payoff can be substantial.
Given that restricting access harms patients, 15 states
and the District of Columbia are taking action, including Delaware,
Maryland, and Louisiana, which passed laws capping co-pays on specialty
medicines. Yet, if the real value of novel therapies is to be realized,
we need more patient protections at the state and federal levels.
Instead of a petition to impose more cost containment policies, now is
the time for a petition to increase patient access to novel therapies
through legislative and regulatory remedies.
Labels: access to new drugs, Aimed Alliance, Alliance for the Adoption of Innovations in Medicine